Recent advancements in double-expressor lymphoma: novel therapeutic approaches and prospects
The Oncologist · 04.06.2025 · 30 (6)
DOI: 10.1093/oncolo/oyaf085 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Oncologist, online erschienen am 17.06.2025. Verfasst von Yuejian Zhuo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Proto-Oncogene Proteins c-bcl-2, Proto-Oncogene Proteins c-myc. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Innovative Research Program of Xiangyang No.1 People's Hospital, Innovative Research Program of Xiangyang No.1 People’s Hospital.
Abstract (Originalsprache)
Double-expressor lymphoma (DEL) is a newly identified special subtype of diffuse large B-cell lymphoma (DLBCL), which is predominantly found in the activated B-cell-like (ABC) subtype of DLBCL. Characterized by concurrent overexpression of BCL2 and MYC, DEL is associated with poorer prognosis. Standard chemoimmunotherapy can achieve clinical cure in nearly 70% of DLBCL cases. DEL mainly presents with intermediate-to-high-risk international prognostic index scores, advanced stage at diagnosis, and may involve specific chromosomal rearrangements, mainly influencing older patients. These factors are interconnected and contribute to less favorable treatment outcomes. We review emerging drugs and clinical trial data potentially effective against DEL, formulating treatment recommendations based on evidence levels to provide a theoretical foundation for the clinical treatment of DEL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China.
ORCID-Profile: Dongdong Zhang
Förderung
- National Natural Science Foundation of China
- Innovative Research Program of Xiangyang No.1 People's Hospital
- Innovative Research Program of Xiangyang No.1 People’s Hospital
Zitieren
APA
Zhuo, Y., & Zhang, D. (2025). Recent advancements in double-expressor lymphoma: novel therapeutic approaches and prospects. The Oncologist, 30(6). https://doi.org/10.1093/oncolo/oyaf085
Vancouver
Zhuo Y, Zhang D. Recent advancements in double-expressor lymphoma: novel therapeutic approaches and prospects. The Oncologist. 2025;30(6). doi:10.1093/oncolo/oyaf085
BibTeX
@article{Zhuo2025,
author = {Zhuo, Yuejian and Zhang, Dongdong},
title = {Recent advancements in double-expressor lymphoma: novel therapeutic approaches and prospects},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {6},
doi = {10.1093/oncolo/oyaf085}
}
EUVIMED